Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study-Reference-Cited by-同舟云学术

Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study

Published:2020-12 Issue:6 Volume:18 Page:477-488
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Vitale Maria Giuseppa,Pipitone Stefania,Venturelli Marta,Baldessari Cinzia,Porta Camillo,Iannuzzi Federica,Basso Umberto,Scagliarini Sarah,Zucali Paolo Andrea,Galli Luca,Rossetti Sabrina,Caserta Claudia,Bracarda Sergio,Iacovelli Roberto,Masini Cristina,Cortellini Alessio,Di Girolamo Stefania,Buti Sebastiano,Fornarini Giuseppe,Carrozza Francesco,Santoni Matteo,Caputo Francesco,Giaquinta Stefania,Balduzzi Sara,D’Amico Roberto,Vitale Giovanna,Mighali Pasquale,Sabbatini Roberto

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference42 articles.

1. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

3. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial;Sharma;Lancet Oncol,2016

4. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016

5. Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures;Şenbabaoglu;Genome Biol,2016

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis;Cancer Treatment Reviews;2024-09

2. Cytokines in PD-1 immune checkpoint inhibitor adverse events and implications for the treatment of uveitis;BMC Ophthalmology;2024-07-29

3. Discontinuation of Immune-oncology Combinations due to Immune-related Adverse Events in Patients With Advanced Renal Cancers;Anticancer Research;2023-12-30

4. Association between immune‐related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis;Fundamental & Clinical Pharmacology;2023-11-27

5. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance;npj Precision Oncology;2023-05-12